Literature DB >> 831761

Fractional incorporation of [3H]thymidine and DNA specific activity as assays of inhibition of tumour growth.

P J Houghton, D M Taylor.   

Abstract

The Fractional Incorporation (FI) of [3H] thymidine ([3H]TdR) has been examined in small lung tumours after cyclophosphamide (CY) treatment in vivo and compared to the DNA specific activity (SA) at different times after treatment. FI was found to correlate with the incidence of labelled cells after treatment, whereas SA did not, due to the loss of DNA from drug-killed cells 72 h after treatment. The FI is independent of the precursor concentration in the tissue, and therefore may give a better index of DNA synthesis in irregularly perfused tissues than SA. Following either CY or 60Co radiation treatment, the time necessary for FI to reach the pretreatment level is quite similar to the growth delay measured for the FI depression 45 h after treatment and growth delay has been established in the Lewis lung tumour, which would allow the prediction of growth delay induced by another agent to be made within 2 days of treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 831761      PMCID: PMC2025308          DOI: 10.1038/bjc.1977.5

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Stem-cell survival and tumor control in the Lewis lung carcinoma.

Authors:  G G Steel; K Adams
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

2.  Effect of x-radiation on DNA metabolism in various tissues of the rat. I. Incorporation of C14-thymidine into DNA during the first 24 hours postirradiation.

Authors:  O F NYGAARD; R L POTTER
Journal:  Radiat Res       Date:  1959-04       Impact factor: 2.841

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Effects of cis-dichlorodiammine platinum (II) on DNA synthesis in kidney and other tissues of normal and tumour-bearing rats.

Authors:  D M Taylor; K D Tew; J D Jones
Journal:  Eur J Cancer       Date:  1976-04       Impact factor: 9.162

5.  Assessment of an in vitro screening test of cytotoxic agents in the treatment of advanced malignant disease.

Authors:  T K Wheeler; P P Dendy; A Dawson
Journal:  Oncology       Date:  1974       Impact factor: 2.935

6.  Effects of chemotherapy on the incorporation of 3 H-thymidine into DNA of human neoplastic tissue.

Authors:  H H Sky-Peck
Journal:  Natl Cancer Inst Monogr       Date:  1971-12

Review 7.  The determination of nucleic acids.

Authors:  H N Munro
Journal:  Methods Biochem Anal       Date:  1966

8.  Modification of folic acid-induced changes in renal nucleic acid and protein synthesis by actinomycin D and cycloheximide.

Authors:  G Threlfall; D M Taylor
Journal:  Eur J Biochem       Date:  1969-04

9.  Serial labeling index determination as a predictor of response in human solid tumors.

Authors:  W K Murphy; R B Livingston; V G Ruiz; F G Gercovich; S L George; J S Hart; E J Freireich
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

10.  The lung-colony assay: extension to the Lewis lung tumour and the B16 melanoma--radiosensitivity of B16 melanoma cells.

Authors:  R P Hill; J A Stanley
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1975-04
View more
  3 in total

1.  Cyclophosphamide and cis-dichlorodiammine platinum (11). Nonempiric scheduling to spare dose-limiting tissues in the rat.

Authors:  K D Tew; D M Taylor
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.

Authors:  R Gagliardi; G Sava; S Pacor; G Mestroni; E Alessio
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

3.  Evaluation of single-agent therapy in human colorectal tumour xenografts.

Authors:  P J Houghton; J A Houghton
Journal:  Br J Cancer       Date:  1978-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.